Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRLD
DateTimeSourceHeadlineSymbolCompany
16/05/202421:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
16/05/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202412:01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202412:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
07/05/202412:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202412:01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202421:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202421:35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202421:45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202422:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202421:05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202421:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202421:05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202421:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
08/01/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202314:34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202314:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202320:05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202317:30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
06/10/202314:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD